SCHEMBL1373983

SCHEMBL1373983

O=C1CCCc2ccccc2O1

nearest known ligand 0.50

Predicted protein targets (top 17)

geneUniProtsupporting neighboursconfidence
MAOB P27338 3/20 0.46
MAOA P21397 2/20 0.46
CYP2A6 P11509 2/20 0.45
TSHR P16473 2/20 0.42
MAPT P10636 2/20 0.41
CYP1A2 P05177 2/20 0.41
KDM4E B2RXH2 1/20 0.41
GLA P06280 1/20 0.41
CYP2C9 P11712 1/20 0.41
HPGD P15428 1/20 0.41
CYP2C19 P33261 1/20 0.41
SIRT1 Q96EB6 1/20 0.41
HSD17B10 Q99714 1/20 0.41
GAA P10253 1/20 0.37
NPSR1 Q6W5P4 1/20 0.37
CES1 P23141 1/20 0.35
MIF P14174 1/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Dihydrocoumarin SCHEMBL28524035 0.88 MAOB (0.46) MAOBMAOACYP2A6TSHRMAPT
Dihydrocoumarin SCHEMBL29350292 0.87 MAOB (0.50) MAOBMAOACYP2A6TSHRCYP1A2
Dihydrocoumarin SCHEMBL28795 0.87 MAOB (0.50) MAOBMAOACYP2A6TSHRCYP1A2
Dihydrocoumarin SCHEMBL17629427 0.87 MAOB (0.50) MAOBMAOACYP2A6TSHRCYP1A2
SCHEMBL27593934 0.87 KDM4E (0.46) MAOBMAOACYP2A6TSHRMAPT
Dihydrocoumarin SCHEMBL28721518 0.85 MAOB (0.48) MAOBMAOACYP2A6TSHRCYP1A2
Dihydrocoumarin SCHEMBL8888209 0.85 MAOB (0.48) MAOBMAOACYP2A6TSHRCYP1A2
Dihydrocoumarin SCHEMBL7617919 0.85 MAOB (0.48) MAOBMAOACYP2A6TSHRCYP1A2
SCHEMBL4500547 0.84 MAOA (0.64) MAOBMAOACYP2A6TSHRMAPT
Dihydrocoumarin SCHEMBL27348538 0.83 MAOB (0.46) MAOBMAOACYP2A6TSHRCYP1A2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 34 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-10640481-B2 Methods for producing Beraprost and its derivatives LUNG BIOTECHNOLOGY PBC (US) 2020-05-05 US disclosed
US-20190202797-A1 METHODS FOR PRODUCING BERAPROST AND ITS DERIVATIVES LUNG BIOTECHNOLOGY PBC (US) 2019-07-04 US disclosed
US-10246430-B2 Methods for producing Beraprost and its derivatives LUNG BIOTECHNOLOGY PBC (US) 2019-04-02 US disclosed
US-10005753-B2 Methods for producing beraprost and its derivatives LUNG BIOTECHNOLOGY PBC (US) 2018-06-26 US disclosed
US-10005753-B2 Methods for producing beraprost and its derivatives LUNG BIOTECHNOLOGY PBC (US) 2018-06-26 US disclosed
US-20170166545-A1 METHODS FOR PRODUCING BERAPROST AND ITS DERIVATIVES LUNG BIOTECHNOLOGY PBC (US) 2017-06-15 US disclosed
US-20170166545-A1 METHODS FOR PRODUCING BERAPROST AND ITS DERIVATIVES LUNG BIOTECHNOLOGY PBC (US) 2017-06-15 US disclosed
WO-2015179427-A1 METHODS FOR PRODUCING BERAPROST AND ITS DERIVATIVES LUNG BIOTECHNOLOGY PBC (US) 2015-11-26 WO disclosed
EP-2502918-B1 Pyridazinone Derivatives CEPHALON INC (US) 2015-03-25 EP disclosed
US-20140142088-A1 PYRIDAZINONE DERIVATIVES CEPHALON, INC. (US) 2014-05-22 US disclosed
US-20090012055-A1 Organic compounds HEROLD PETER 2009-01-08 US disclosed
EP-1961752-A2 Piperidine Compounds Speedel Experimenta AG (CH) 2008-08-27 EP disclosed
WO-2008013838-A2 PYRIDIZINONE DERIVATIVES CEPHALON, INC. (US) 2008-01-31 WO disclosed
US-20080027041-A1 Pyridizinone derivatives CEPHALON, INC. (US) 2008-01-31 US disclosed
EP-1851190-A1 COMPOSITIONS AND METHODS FOR INHIBITING PAIN University of Florida (US) 2007-11-07 EP disclosed
US-20070010511-A1 Organic compounds NOVARTIS PHARMA AG (CH) 2007-01-11 US disclosed
WO-2006078239-A1 COMPOSITIONS AND METHODS FOR INHIBITING PAIN UNIVERSITY OF FLORIDA (US) 2006-07-27 WO disclosed
US-20060160905-A1 Compositions and methods for inhibiting pain UNIVERSITY OF FLORIDA 2006-07-20 US disclosed
EP-1670760-A1 ORGANIC COMPOUNDS Speedel Experimenta AG (CH) 2006-06-21 EP disclosed
WO-2005061457-A1 ORGANIC COMPOUNDS SPEEDEL EXPERIMENTA AG (CH) 2005-07-07 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (10 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20170166545-A1 METHODS FOR PRODUCING BERAPROST AND ITS DERIVATIVES CYP51A1, COASY, BLVRB MAOB 485/4885MAOA 676/4885CYP2A6 42/4885
US-20090012055-A1 Organic compounds REN, ACE, ACE2 MAOB 43/4885MAOA 85/4885CYP2A6 95/4885
US-20070010511-A1 Organic compounds REN, ACE, ACE2 MAOB 43/4885MAOA 85/4885CYP2A6 95/4885
US-10246430-B2 Methods for producing Beraprost and its derivatives UMPS, GGPS1, DHPS MAOB 971/4885MAOA 1104/4885CYP2A6 458/4885
US-20080027041-A1 Pyridizinone derivatives H1-5, H1-3, H1-4 MAOB 318/4885MAOA 471/4885CYP2A6 640/4885
US-10005753-B2 Methods for producing beraprost and its derivatives CYP51A1, COASY, BLVRB MAOB 485/4885MAOA 676/4885CYP2A6 42/4885
US-10640481-B2 Methods for producing Beraprost and its derivatives UMPS, GGPS1, DHPS MAOB 971/4885MAOA 1104/4885CYP2A6 458/4885
US-20140142088-A1 PYRIDAZINONE DERIVATIVES HRH3, HNMT, HRH4 MAOB 36/4885MAOA 38/4885CYP2A6 328/4885
US-20060160905-A1 Compositions and methods for inhibiting pain OPRM1, OPRL1, OPRK1 MAOB 826/4885MAOA 539/4885CYP2A6 584/4885
US-20190202797-A1 METHODS FOR PRODUCING BERAPROST AND ITS DERIVATIVES UMPS, GGPS1, DHPS MAOB 971/4885MAOA 1104/4885CYP2A6 458/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.